Guildford, UK, 21 December 2010: ReNeuron Group plc (LSE: RENE.L) is today pleased to announce that, following a positive independent safety review of progress of the first patient treated in the PISCES clinical trial of ReNeuron’s ReN001 stem cell therapy for stroke, the clinical trial will now progress to treatment of the remainder of the first patient cohort.

More…

Guildford, UK, 20 December 2010: ReNeuron Group plc (LSE: RENE.L) announced on 13 December 2010 that it had raised £10 million, before expenses (the “Fundraising”), by means of:
·    a placing (the “Placing”), with new and existing investors, of 181,318,182 new Ordinary Shares of 1 pence each (the “Ordinary Shares”) (the “Placing Shares”) at a price of 5.5 pence per new Ordinary Share; and
·    a subscription (the “Subscription”), by the Directors, for 500,000 new Ordinary Shares of 1 pence each (the “Subscription Shares”) also at a price of 5.5 pence per new Ordinary Share.

More…

Guildford, UK, 17 December 2010: ReNeuron Group plc (LSE: RENE.L) announced on 13 December 2010 that it had raised £10 million, before expenses (the “Fundraising”), by means of:
·    a placing (the “Placing”), with new and existing investors, of 181,318,182 new Ordinary Shares of 1 pence each (the “Ordinary Shares”) (the “Placing Shares”) at a price of 5.5 pence per new Ordinary Share; and
·    a subscription (the “Subscription”), by the Directors, for 500,000 new Ordinary Shares of 1 pence each (the “Subscription Shares”) also at a price of 5.5 pence per new Ordinary Share.

More…

Full details can be downloaded below:

More…

Guildford, UK, 13 December 2010: ReNeuron Group plc (LSE: RENE.L) today announces that it has raised £10 million, before expenses (the “Fundraising”), by means of:
·    a placing (the “Placing”), with new and existing investors, of 181,318,182 new Ordinary Shares of 1 pence each (the “Ordinary Shares”) (the “Placing Shares”) at a price of 5.5 pence per new Ordinary Share; and
·    a subscription (the “Subscription”), by the Directors, for 500,000 new Ordinary Shares of 1 pence each (the “Subscription Shares”) also at a price of 5.5 pence per new Ordinary Share.

More…

Guildford, UK, 17 November 2010: ReNeuron Group plc (LSE: RENE.L) today provides an update on progress with its ReN009 stem cell therapy for peripheral arterial disease (PAD).  PAD is a chronic and debilitating disease that progressively restricts blood flow in the limbs, causing cramping, chronic pain and in extreme cases, amputation.  PAD is commonly associated with other conditions, including diabetes, obesity and stroke.  At least 1 in 20 people over the age of 55 have some degree of PAD and it becomes more common with increasing age.

More…

• First ever clinical trial in stroke using expanded neural stem cells

• First company to gain approval to undertake stem cell trial in the UK

• Promotes clinical innovation in the NHS

More…

Guildford, UK, 27 October 2010: ReNeuron Group plc (LSE: RENE.L) announces that it will be presenting at the Translational Neuroscience 2010 conference taking place in Frankfurt, Germany on 27-28 October and at the Stem Cell Society Singapore Symposium 2010, taking place in Singapore on 2-3 November 2010. At both conferences, Dr John Sinden, Chief Scientific Officer of ReNeuron, will outline the methodology and challenges in taking ReNeuron’s ReN001 stem cell therapy for disabled stroke patients from the laboratory bench to a ground-breaking first in-man clinical trial in the UK.

More…

Guildford, UK, 8 October 2010: ReNeuron Group plc (LSE: RENE.L) announces that it will be presenting at next week’s 18th Annual BioPartnering Europe conference at the QEII Conference Centre, London. Michael Hunt, Chief Executive Officer of ReNeuron, will take part in a Leadership Session panel discussion, hosted by Ferghana Partners, Inc. The panel will focus on the incremental impact of regenerative medicine and cell-based therapies and the business and partnering models being adopted by players operating in this field.

More…

Guildford, UK, 21 September 2010: ReNeuron Group plc (LSE: RENE.L) announces that it is presenting at a key UK regenerative medicine conference.  The conference, “Exploiting Market Opportunities in Regenerative Medicine” has been organised by the Technology Strategy Board (a body sponsored by the UK Government’s Department of Business, Innovation and Skills) and is taking place today at the King’s Fund, Cavendish Square, London.   

More…